Impact of an Artificial Intelligence Platform on Inappropriate Medication Use in Older Adults (PING)

University Hospital of Bordeaux

Status: Enrolling

Conditions: Geriatric Disease; Drug-drug Interactions

Treatments: Device: Synapse platform

Study type: Interventional

Funder types: Other

Identifiers

NCT04710615

CHUBX 2019/33

Details and patient eligibility

About

Polypharmacy in the older adults is common and promotes the risk of drug interactions. The hypothesis evoked is that a virtual platform with artificial intelligence applied to the health, and in particular to the good use of the drug, could bring aids to the doctors them of the prescription of drugs. The main objective of this study is to evaluate the impact of geriatric use of the Synapse platform on the frequency of inappropriate medication prescriptions (STOPP criteria) in discharge orders for patients 65 years of age or older hospitalized in geriatric department.

Full description

The French 2018-2022 National Health Strategy plan aims to reduce the proportion of potentially harmful medication use. One particular challenge is the phenomenon of polypharmacy and inappropriate medication use in elderly, which is associated to an increased risk of drug-drug interactions. Several scales and tools have been proposed to identify inappropriate drugs prescription in older adults. Among them, the STOPP / START criteria (Screening Tool of Older Persons' Prescriptions / Screening Tool to Alert to Right Treatment) are internationally recognized.

The Synapse platform offers a panel of functions that may help physicians to prescribe medications. For instance, the prescriber can interact with the Synapse platform by asking any type of question about a drug (dosage, contraindication, interaction ...) before prescription. It also allows them to take a picture of prescription. The software detects in less than 10 seconds criteria for inappropriate medication prescriptions and potential drug-drug interactions.

More precisely, the Synapse platform provides information on a particular drug or prescription analysis regarding:

• Indications, contraindications, dosage and adverse effects of drugs.
• STOPP criteria.
• START criteria.
• Associations at risk for drug-drug interactions.

Multiple new health technologies are emerging, but few of them have demonstrated their scientific and medical added value using an evidence-based medicine approach.

This clinical trial aims to validate the clinical interest of the Synapse application in a geriatric environment.

Prescriptions made by geriatricians participating in this study will be analyzed by two independent experts, including one pharmacist and one geriatrician.

Enrollment: 200 estimated patients

Sex: All

Ages: 65+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

• Inclusion criteria:

  • Male or female age aged more than 65 years
  • Hospitalization in geriatric department at Bordeaux University Hospital or Libourne Hospital
  • Initial drug prescription with at least 2 active pharmaceutical ingredients
  • Affiliation to French social security
  • Written informed consent signed by participant and investigator

• Exclusion criteria:

  • Adults protected by law
  • Subject included in a clinical trial with an experimental treatment
  • Subject during exclusion period relative to another trial

Trial design

Primary purpose: Health Services Research

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

200 participants in 2 patient groups

Assistance device

Experimental group

Description:

With prescription assistance device: During the other 3 months, investigators will have the Synapse platform on different media (mobile phones, tablets, laptops and landline).

Treatment:

Device: Synapse platform

No device

No Intervention group

Description:

During 3 months, investigators will not have the Synapse platform and will make their prescriptions with the usual tools which they have: Modules of help in the DxCare® software of the CHU, public database of the drugs, dictionary Vidal®, ...